Cbdmd (YCBD) revenue and earnings history
Cbdmd reported revenue of $19.2M for fiscal 2025 (year ended Sep 30, 2025), −1.5% on the year before, and net income of −$2.04M.
Over 9 years, from fiscal 2016 to fiscal 2025, revenue grew at a compound rate of +28.3% a year.
Revenue and net income, 10 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Sep 30, 2025 | $19.2M−1.5% | −$2.16M | −$2.04M | −$1.45M | $184K | −$1.64M | — | — | — | $2.26M | — | 10-K |
| 2024ended Sep 30, 2024 |
The latest quarter, insider trades and fund moves: Cbdmd (YCBD) on OQRO.
Common questions
What was Cbdmd's revenue in fiscal 2025?
$19.2M for the year ended Sep 30, 2025, as reported in its 10-K filed Dec 19, 2025. That is −1.5% on fiscal 2024 ($19.5M).
How fast has Cbdmd's revenue grown?
From $2.03M in fiscal 2016 to $19.2M in fiscal 2025: a compound annual growth rate of +28.3% over 9 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Cbdmd been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Cbdmd tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
